Analysis of the responsible genome by the next generation sequencing (NGS) for drug sensitivity and prediction of prognosis in patients with newly diagnosed untreated multiple myeloma
Not Applicable
Recruiting
- Conditions
- Multiple Myeloma
- Registration Number
- JPRN-UMIN000025835
- Lead Sponsor
- ational Hospital Organization,
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 150
Inclusion Criteria
Not provided
Exclusion Criteria
1. 19 years or younger 2. Patients identified as ineligible by the directors and co-working of each institute.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Progression free survival (PFS) in each of the baseline genomic subgroup of at diagnosis.
- Secondary Outcome Measures
Name Time Method Correlation of PFS and quantity of tumor element evaluated three months after the start of therapy Correlation of PFS and quantity of tumor element evaluated six months after the start of therapy Correlation of TNT and quantity of tumor element evaluated three months after the start of therapy Correlation of TNT and quantity of tumor element evaluated six months after the start of therapy Genetic mutations of myeloma cells associated with treatment